Positron emission tomography (PET) and single photon emission tomography (SPET) permit the in vivo assesment of human biological processes with methods originally developed for preclinical studies. This opportunity is of primary interest in biological psychiatry and in psychoactive drugs development. Most of research efforts have focused on the use of PET field, and several biological finding on central nervous system (CNS) diseases have been published. Despite methodological limitations, the feasibility and usefulness of SPET for research, including full quantification, kinetic modeling and tracer validation, has been clearly demonstrated. The AIM: of this paper is to review advantages, limitations and results of SPET in psychopharmacology.
Moresco, R., Fazio, F. (2005). SPET in psychopharmacolgy. THE QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 49(2), 205-214.
SPET in psychopharmacolgy
MORESCO, ROSA MARIA;FAZIO, FERRUCCIO
2005
Abstract
Positron emission tomography (PET) and single photon emission tomography (SPET) permit the in vivo assesment of human biological processes with methods originally developed for preclinical studies. This opportunity is of primary interest in biological psychiatry and in psychoactive drugs development. Most of research efforts have focused on the use of PET field, and several biological finding on central nervous system (CNS) diseases have been published. Despite methodological limitations, the feasibility and usefulness of SPET for research, including full quantification, kinetic modeling and tracer validation, has been clearly demonstrated. The AIM: of this paper is to review advantages, limitations and results of SPET in psychopharmacology.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
